Sustainable Cosmetic Products
Consumers are increasingly looking for transparency and authenticity in cosmetic products brands. Choosing sustainable ingredients, environmentally friendly packaging and truthful labelling claims are important steps to achieve the "sustainable brand" status. Three essential pillars should be considered in this process: environmental protection, corporate social responsibility and ethical governance.

SUSTAINABILITY AND TRANSPARENCY OF THE COSMETIC INDUSTRY

The United Nations (UN) developed a global sustainable framework which set 17 Sustainable Development Goals. The main objective is to protect the planet. These goals are considered the “blueprint to achieve a better and more sustainable future for all”. A more sustainable production and consumption represents a critical step in this process.

Innovation and sustainability go hand in hand. The cosmetic industry continues to innovate and find new ingredients, not always considering its entire supply chain and their environmental impact. Formulation, production, use and disposal of packaging of cosmetic products can all have a big impact on the planet. Therefore, biodegradable, natural and organic products are more and more demanded by consumers.

Consumers want more transparency from cosmetic companies. Many of them demand to know which ingredients are used and which supply chains were chosen (especially the sources). Furthermore, they claim for clearer language and informations used in the labelling.

The beauty industry is under increased scrutiny by society and more responsible sourcing is being demanded across all markets. Environmentally-friendly ingredients, increased transparency practices and use of recycled (or recyclable) packaging are essential keys to achieve the sustainability status and actually contribute to make the difference.

Cosmetic companies should consider the traceability of natural ingredients and the degree to which they have been sourced in a sustainable fashion (e.g. ethical and responsible sourcing, fair-trade). It is essential to work with third parties (e.g. suppliers, manufacturers) that can provide documentation to support supply chain transparency. Non-sustainable sources of ingredients, such as animal, petrochemical and endangered plants, should be increasingly avoided at all costs.

THE ENVIRONMENTAL CAUSE – ECO-FRIENDLY CERTIFICATION

As discussed in one of our previous posts, there are international guidelines (ISO 16128) for technical definitions and criteria regarding natural and organic cosmetics. However, more guidelines are needed when talking about clean, eco-friendly and sustainable products. These should cover responsible sourcing and stablish standards for higher degrees of transparency.

Certifications are essential to prove certain types of claims (e.g. natural and organic) in cosmetic products. Certification entails investment and can be expensive, particularly for smaller brands. Nevertheless, certification can represent an increase on consumers trust on the brand and, consequently, either lead to more sales or ease brand’s access to new and more demanding markets.

Consumer demands are shaping the cosmetics industry and making it more sustainable and ‘eco-friendly’. Producing ‘eco-friendly’ cosmetics will increase the company’s reputation, improve product quality and lower the negative impact that its products have on the planet.

CORPORATE SOCIAL RESPONSIBILITY & ETHICAL GOVERNANCE

Corporate social responsibility (CSR) is a type of international private business self-regulation that aims to contribute to societal goals of a philanthropic, activist, or charitable nature by engaging in or supporting volunteering or ethically-oriented practices. Various international laws have been developed and various organisations have used their authority to push it beyond individual or even industry-wide initiatives. Over the last decade or so it has moved considerably from voluntary decisions at the level of individual organizations to mandatory schemes at regional, national, and international levels.

Considered at the organisational level, CSR is generally understood as a strategic initiative that contributes to a brand’s reputation. As such, social responsibility initiatives must coherently align with and be integrated into the company’s business model to be successful. With some models, a firm’s implementation of CSR goes beyond compliance with regulatory requirements and engages in “actions that appear to further some social good, beyond the interests of the firm and that which is required by law“.

Furthermore, businesses may engage in CSR for strategic or ethical purposes. From a strategic perspective, CSR can contribute to firm profits, particularly if brands voluntarily self-report both the positive and negative outcomes of their endeavours. In part, these benefits accrue by increasing positive public relations and high ethical standards to reduce business and legal risk by taking responsibility for corporate actions.

The sustainable status encourages companies not only to make a positive impact on the environment but also on all the other stakeholders including consumers, employees, investors and communities.cNot sure of how to make your brand more sustainable? Feel free to contact us at info@criticalcatalyst.com

References:

  1. Sustainable Development Goals. United Nations. Available from: https://www.un.org/sustainabledevelopment/sustainable-development-goals/
  2. ISO 16128-1:2016. Cosmetics — Guidelines on technical definitions and criteria for natural and organic cosmetic ingredients – Part 1: Definitions for ingredients.
  3. ISO 16128-2:2017. Cosmetics — Guidelines on technical definitions and criteria for natural and organic cosmetic ingredients – Part 2: Criteria for ingredients and products.
  4. Johnson, Zachary; Ashoori, Minoo; Lee, Yun (2018). “Self-Reporting CSR Activities: When Your Company Harms, Do You Self-Disclose?”. Corporate Reputation Review. 21 (4): 153–164.

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »